image

What are Anti-Idiotypic Antibodies?

Anti-idiotypic antibodies are antibodies that bind to the idiotype of another antibody or biologic, typically an antibody drug. Anti-ids are important downstream reagents for specific drug development assays (e.g. PK and ADA), as well as many other applications such as diagnostic assays and biomarker discovery and evaluation.

There are different ways an anti-idiotypic antibody can interact with an antibody via different regions. The key success factor for the development is the understanding of the intended applications and design of proper screening cascades for the selection of ideal anti-idiotypic antibodies. Twist Biopharma Solutions develops industry-leading technologies and workflows that will drastically enhance the success of anti-idiotypic antibody discovery campaigns.

Anti-Idiotypic Antibody Discovery Services

At Twist Biopharma Solutions, we approach your drug development endeavors with the end goal in mind. Anti-idiotypic (anti-ids) antibodies play a pivotal role in the preclinical journey by serving as valuable reagents for quality control, ensuring the specificity and efficacy of therapeutic antibodies. These antibody tools are essential for assessing the immunogenicity and safety profiles of biologics, aiding in the detection of unwanted immune responses and ultimately accelerating the development of novel therapies with improved efficacy and safety profiles.

Superior Antibody Diversity icon

Twist's platform produces a diverse panel of target specific anti-idiotypic antibodies using our proprietary hyperimmune DiversimAb™ Mouse.

Advanced Affinity and Specificity Screenings

Industry-leading, function-forward screening packages offer anti-ids stringently screened for binding affinity in the presence of human serum using both ELISA and BLI to deliver ideal antibodies ready for validation assays.

Rapid, Predictable Project Timelines

Twist devises an industry-leading anti-idiotypic antibody discovery platform that offers either single B-cell screening or integrated hybridoma workflows to de-risk projects and improve the predictability of timelines.

Proven Expertise and 97% Success Rate

250+ successful anti-idiotypic antibody programs.

97% success rate based on project requirements.

Success in different therapeutic modalities, including monoclonal antibodies, bispecifics, ADCs, and cell therapy products.

Anti-Idiotypic Antibody Workflows, Customized for your Development Program

graph

Twist’s Anti-Id Guarantee

Our anti-idiotypic guarantee promises delivery of anti-idiotypic antibodies capable of binding specifically to your target biologic. If we don’t find at least one antibody that’s specific to your target, we will perform an additional screen for FREE.

What Scientists Have to Say

I can always trust that I’ll have no surprises when I’m working with the Twist Biopharma Solutions team, and that’s why I continue to come back. I’ve outsourced dozens of anti-id programs during my career and there have been too many times where simple oversights have cost me 6+ months in assay development. For these high-impact translational programs, it’s critical we get it right the first time.”

 

 

Director of Translational Development

Biopharma

At Promega, we struggled to acquire a high-affinity, high-specificity antibody against one target of interest. After failing with two previous vendors, we enlisted the help of Twist Biopharma Solutions and their DiversimAb approach, and we soon had a multitude of high-quality clones to choose from. We eventually chose a clone that far exceeded our expectations for performance. We were continually impressed by their high-quality analytical data, excellent communication, and overall collaborative spirit.”

 

Promega Corporation

Explore More

Anti-Idiotypic Antibody Discovery Service Sheet

Product SheetAntibodies

Download the product sheet

DiversimAb™ Mouse for Antibody Discovery

Product sheet Biopharma

Download the product sheet

Twist Express Antibody Production

Product SheetBiopharma

Twist Express Antibody Production

Antibody Characterization and Developability

WebinarBiopharma

View the presentation

Get in Touch With Us

Antibody enthusiasts are standing by and would love to hear more about your discovery needs. Challenging targets welcome!